| Identification | Back Directory | [Name]
4-Hydroxy-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-methyl-1-piperidinecarboxamide | [CAS]
870070-55-6 | [Synonyms]
CS-297
SYN-115
Tozadenant
Tozadenant (SYN-115)
SYN-115 (Tozadenant)
SYN-115;SYN115;SYN 115
4-Hydroxy-N-[4-methoxy-7-...
4-Methoxy-7-morpholino-2-[(4-hydroxy-4-methylpiperidino)carbonylamino]benzothiazole
4-hydroxy-N-(4-methoxy-7-morpholinobenzo[d]thiazol-2-yl)-4-methylpiperidine-1-carboxamide
4-Hydroxy-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-methyl-1-piperidinecarboxamide
1-Piperidinecarboxamide, 4-hydroxy-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-methyl- | [Molecular Formula]
C19H26N4O4S | [MDL Number]
MFCD21642026 | [MOL File]
870070-55-6.mol | [Molecular Weight]
406.5 |
| Chemical Properties | Back Directory | [density ]
1.374 | [storage temp. ]
Store at -20°C | [solubility ]
insoluble in EtOH; insoluble in H2O; ≥20.35 mg/mL in DMSO | [form ]
Powder | [pka]
14.95±0.20(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Description]
Tozadenant is an adenosine A2A receptor antagonist (Kis = 11.5 and 6 nM for the human and rhesus monkey receptors, respectively). It increases the distance traveled and reduces contralateral asymmetry in the open field test in a rat model of Parkinson''s disease induced by 6-OHDA when administered at a dose of 30 mg/kg. Tozadenant (150 mg/kg) reverses locomotor deficits and restores novel object-stimulated locomotion in a marmoset model of MPTP-induced Parkinson''s disease. | [Uses]
Tozadenant is an adenosine A2A receptor antagonist, with Ki of 11.5 nM on human A2A and 6 nM on rhesus A2A. | [Definition]
ChEBI: Tozadenant is a member of benzothiazoles. | [in vivo]
18F-MNI-444 regional uptake is consistent with A2A receptor distribution in the brain. Selectivity is demonstrated by dose-dependent blocking by tozadenant (1.5, 10.5 mg/kg) and preladenant[1]. | [target]
adenosine A2A receptor | [References]
hauser ra, olanow cw, kieburtz kd et al. tozadenant (syn115) in patients with parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. lancet neurol. 2014 aug;13(8):767-76. |
|
| Company Name: |
Tetranov Biopharm
|
| Tel: |
13526569071 |
| Website: |
http://www.leadmedpharm.com/index.html |
|